О МЕХАНИЗМЕ РЕМОДЕЛИРОВАНИЯ МИОКАРДА В ОСТРЕЙШУЮ ФАЗУ ЭКСПЕРИМЕНТАЛЬНОГО ИНФАРКТА МИОКАРДА

DOI: https://doi.org/None

С.А. Крыжановский, доктор медицинских наук, Е.О. Ионова, В.Н. Столярук, кандидат медицинских наук, И.Б. Цорин, доктор биологических наук, М.Б. Вититнова, кандидат биологических наук Научно-иследовательский институт фармакологии им. В.В. Закусова, Российская Федерация, 125315, Москва, Балтийская ул., д. 8 E-mail: [email protected]

Цель исследования – изучение особенностей ремоделирования левого желудочка (ЛЖ) сердца в острейшую стадию экспериментального инфаркта миокарда (ИМ) и возможности коррекции выявленных нарушений. Методы. Экспериментальный ИМ у крыс вызывали одномоментной перевязкой левой нисходящей коронарной артерии. Животных рандомизировали на 3 группы: 1-я – ложнооперированные (n=6), 2-я – острый ИМ (ОИМ; n=12), 3-я – доксициклин + ОИМ (n=9). Эхокардиографическую оценку динамики изменения геометрии ЛЖ сердца производили до и после вскрытия грудной клетки и через 3, 10, 15, 20, 30, 45 и 60 мин от момента перевязки коронарной артерии. Результаты. Одномоментная перевязка коронарной артерии влекла за собой выраженные изменения в геометрии ЛЖ сердца, максимальные – к 20-й минуте ишемии. Так, конечный систолический размер (КСР) по сравнению с фоновым показателем увеличился с 1,9 до 3,8 мм (p
Ключевые слова: 
инфаркт миокарда, острейшая фаза, эхокардиография, ремоделирование, внезапная сердечная смерть, металлопротеиназы
Для цитирования: 
Крыжановский С.А., Ионова Е.О., Столярук В.Н., Цорин И.Б., Вититнова М.Б. О МЕХАНИЗМЕ РЕМОДЕЛИРОВАНИЯ МИОКАРДА В ОСТРЕЙШУЮ ФАЗУ ЭКСПЕРИМЕНТАЛЬНОГО ИНФАРКТА МИОКАРДА. Молекулярная медицина, 2016; (1): -

Список литературы: 
  1. Kitabayashi K., Siltanen A., Patila T. et al. Bcl-2 expression enhances myoblast sheet transplantation therapy for acute myocardial infarction. Cell. Transplant. 2010; 19 (5): 573–88.
  2. Herrmann J.L., Abarbanell A.M., Wang Y, et al. Transforming growth factor-α enchances stem cell-mediated postischemic myocardial protection. Ann. Thorac. Surg. 2011; 92 (5): 1719–25.
  3. Dayan A., Feinberg M.S., Holbova R. et al. Swimming exercise training prior to acute myocardial infarction attenuates left ventricular remodeling and improves left ventricular function in rats. Ann. Clin. Lab. Sci. 2005; 35 (1): 73–8.
  4. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol. Rev. 2007; 87: 1285–342.
  5. Judgutt B.I. Ischemia/infarction. Heart Fail. Clin. 2012; 8 (1): 43–51.
  6. Vacek T.P., Metreveli N., Tyagi N., Vacek J.C., Pagni S., Tyagi S.C. Electrical stimulation of cardiomyocytes activates mitochondrial matrix metalloproteinase causing elecrtical remodeling. Biochem. Biophys. Res. Commun. 2011; 404 (3): 762–6.
  7. Gallagher G.L., Jackson C.J., Hunyor S.N. Myocardial extracellular matrix remodeling in ischemic heart failure. Front. Biosci. 2007; 12: 1410–9.
  8. Гасанов А.Г., Бершова Т.В. Роль изменений внеклеточного матрикса при возникновении сердечно-сосудистых заболеваний. Биомед. химия. 2009; 55 (2): 155–68. [Gasanov A.G., Bershova T.V. The role of changes of matrix metalloproteinase in cardiovascular diseases. Biomed Khim. 2009; 55 (2): 155–68 (in Russian)]
  9. Shamhart P.E., Meszaros J.G. Non-fibrillar collagens: key mediators of post-infarction cardiac remodeling? J. Mol. Cell. Cardiol. 2010; 48 (3): 530–7.
  10. Lang R.M., Bierig M., Devereux R.B. et al. Recomendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Camber Quantification Writing Group, developed in conjunction with European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005; 18: 1440–63.
  11. Martinez P.F., Okoshi K., Zornoff L.A.M., Oliveira S.A., Campos D.H., Lima A.R., Damatto R.L., Cezar M.D., Bonomo C., Guizoni D.M., Padovani C.R., Cicogna A.C., Okoshi M.P. Echocardiographic detection of congestive heart failure in postinfarction rats. J. Appl. Physiol. 2011; 111 (2): 543–51.
  12. Sun S., Wang X., Qu X., Li Y., Yu Y., Song Y., Wang S.J. Increased expression of myocardial semaphorin 3A in isoproterenol-induced heart failure rats. Chin. Med. J. 2011; 124 (14): 2173–8.
  13. Крыжановский С.А., Ионова Е.О., Столярук В.Н., Цорин И.Б., Вититнова М.Б. Возможность использования эхокардиографии для изучения постинфарктного ремоделирования сердца у мелких животных. Инновации в современной фармакологии. М.: Фолиум, 102.[Kryzhanovskii S.A., Ionova E.O., Stolyaruk V.N., Tsorin I.B., Vititnova M.B. The ability of the echocardiography use to study postinfarction cardiac remodeling in small animals. Innovations in modern pharmacology. M.: Folium, 102 (in Russian)]
  14. Abbate A., Narula J. Role of apoptosis in adverse ventricular remodeling. Heart Fail. Clin. 2012; 8 (1): 79–86.
  15. Seropian I.M., Toldo S., Van Tassel B.W., Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J. Am. Coll. Cardiol. 2014; 63 (16): 1593–603.
  16. Saridakis N.S., Toumanidis S.T., Vintzileou A.M. et al. Effect of dobutamine on left ventricular functional geometry after acute myocardial infarction: experimental study. Hellenic J. Cardiol. (HJC). 2007; 48: 72–9.
  17. Campbell R.W.F., Murray A., Julian D.G. Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study. Br. Heart J. 1981; 46: 351–7.
  18. Zipes D.P., Camm A.J., Borggrefe M. et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2006; 48: 247–346.
  19. Pokorný J., Staněk V., Vrána M. Sudden cardiac death thirty years ago and at present. The role of autonomic disturbaces in acute myocardial infarction revisited. Physiol. Res. 2001; 60 (5): 715–28.
  20. Falk E., Nakano M., Bentzon J.F., Finn A.V., Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur. Heart. J. 2013; 34 (10): 719–28.
  21. Kuller L.H., Cooper M., Perper J., Fisher R. Myocardial infarction and sudden death in an urban community. Bull. N.Y. Acad. Med. 1973; 49 (6): 532–43.
  22. Hearse D.J., Ferrari R., Sutherland F.J. Cardioprotection: Intermittent ventricular fibrillation and rapid pacing can induce preconditioning in the blood-perfused rat heart. J. Mol. Cell. Cardiol. 1999; 31 (11): 1961–73.
  23. Yan G.X., Joshi A., Guo D. et al. Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation. 2004; 110 (9): 1036–41.
  24. Štengl M. Experimental models of spontaneous ventricular arrhythmias and of sudden cardiac death. Physiol. Res. 2010; 59 (1): 25–31.
  25. Curtis M.J. Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischemia-induced ventricular fibrillation. Cardiovasc. Res. 1998; 39: 194–215.
  26. Swann M.H., Nakagawa H., Vanoli E. et al. Heterogeneous regional endocardial repolarization is associated with increased risk for ischemia-dependent ventricular fibrillation after myocardial infarction. J. Cardiovasc. Electrophysiol. 2003; 14 (8): 873–9.
  27. Takahashi T., van Dessel P., Lopshire J.C. et al. Optical mapping of the functional reentrant circuit of ventricular tachycardia in acute myocardial infarction. Heart Rhythm. 2004; 1 (4): 451–9.
  28. Crisu D. Sudden death and ventricular arrhythmias risk stratification after myocardial infarction. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2010;114 (1): 13–9.
  29. Myerburg R.J., Junttila M.J. Sudden cardiac death. Sudden cardiac death caused by coronary heart disease. Circulation. 2012; 125: 1043–52.
  30. Rudic B., Veltmann C., Kuntz E. et al. Early repolarization pattern is associated with ventricular fibrillation in patients with acute myocardial infarction. Heart Rhythm. 2012; 9 (8): 1295–300.
  31. Chung S.S. Early identification of risk factors for sudden cardiac death. Nat. Rev. Cardiol. 2010; 7 (6): 318–26.
  32. El-Sherif N., Khan A., Savarese J., Turitto G. Pathophysiology, risk stratification, and management of sudden cardiac death in coronary artery disease. Cardiology J. 2010;17 (1): 4–10.
  33. Santangeli P., Dello Russo A., Casella M. et al. Left ventricular ejection fraction for the risk stratification of sudden cardiac death: friend or foe? Internal. Med. J. 2011; 41: 55–60.
  34. Clements-Jewery H., Hearse D.J., Curtis M.J. Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation. British J. Pharmacol. 2005; 145 (5): 551–64.
  35. de Groot J.R., Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc. Res. 2004; 62: 323–34.
  36. Ali M.A., Fan X., Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc. Med. 2011; 21 (4):112–8.
  37. Halade G.V., Jin Y.F., Lindsey M.L. Matrix metalloproteinas (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol. Ther. 2013; 139 (1): 32–40.
  38. Hughes B.G., Schulz R. Targeting MMP-2 to treat ischemic heart injury. Basic Res. Cardiol. 2014; 109 (4): 424.
  39. Kandasamy A.D., Chow A.K., Ali M.A., Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc. Res. 2010; 85 (3): 413–23.
  40. Hughes B.G., Fan X., Cho W.J., Schulz R. MMP-2 is localized to the mitochondria-associated membrane of the heart. Am. J. Physiol. Heart Circ. Physiol. 2014; 306 (5): 764–70.
  41. Bench T.J., Jeremias A., Brown D.L. Matrix metalloproteinase inhinbiton with tetracyclines for the treatment of coronary artery disease. Pharmacological Research. 2011; 64: 561–6.
  42. Griffin M.O., Fricovsky E., Ceballos G., Villarreal F. Tetracyclines: a pleotropic family of compounds with promising therapeutic properties. Review of the literature. Am. J. Physiol. Cell. Physiol. 2010; 299: 539–48.
  43. Fana X.Z., Zhu H.J., Wu X., Yan J., Xu J., Wang D.G. Effects of doxycycline on cx43 distribution and cardiac arrhythmia susceptibility of rats after myocardial infarction. Iran. J. Pharm. Res. 2014; 13 (2): 613–21.